Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Subcutaneous vs Intramuscular Testosterone

The Practical Shift in Injection Route and Its Evidence

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Testosterone esters FDA Approved; an FDA-approved subcutaneous autoinjector (Xyosted, enanthate) exists
WADA
Prohibited (S1 Anabolic Agent)

Reference only. Not medical advice.

What can go wrong

SubQ injection can cause local irritation, lumps, or oil leakage, and very thin men may have limited subcutaneous tissue. Despite long-standing belief that oil-based testosterone must go intramuscularly, the accumulated evidence does not show subQ to be less effective. Both routes are effective when properly prescribed and administered.

This is something to take to a clinician. The Atlas can tell you what is known about subcutaneous vs intramuscular testosterone in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Subcutaneous (subQ) injection of testosterone into fat, typically with a short insulin-style needle, has largely displaced deep intramuscular (IM) injection in many TRT clinics. Multiple studies and an FDA-approved subcutaneous enanthate autoinjector (Xyosted) support subQ as achieving comparable total testosterone with a potentially gentler side-effect profile. The shift is real and evidence-backed, not merely a marketing convenience.

A shorter needle, a shallower stick, and comparable testosterone.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Reducing injection pain/anxiety
  • Easier self-administration
  • Potentially lower post-dose hematocrit and estradiol
  • Stable absorption

How it works

Subcutaneous fat is less vascular than muscle, so the oil depot releases testosterone more gradually, producing a smoother absorption curve. The slower release is the proposed reason some studies find lower post-therapy hematocrit and estradiol with subQ versus IM at comparable doses.

Absorption
SubQ slower/smoother; IM faster with larger peaks
Comparable TT
Yes, at equivalent doses
Post-dose hematocrit
Some data favor subQ (lower)
Post-dose estradiol
Some data favor subQ (lower)

Safety in detail

This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Route changes should still be paired with lab follow-up.

Replacement is not the same as a cycle

Replacement dosing by either route targets the physiological range. SubQ's smoother curve does not neutralize the risks of supraphysiological weekly totals; route is a comfort and side-effect-smoothing decision, not a license to dose higher.

What it does to fertility

Route of injection does not change testosterone's suppression of the HPG axis; both subQ and IM exogenous testosterone suppress LH/FSH and spermatogenesis. Fertility-preserving adjuncts (hCG, SERMs) are independent of route.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Total testosterone (trough)
  • Estradiol
  • Hematocrit/CBC
  • PSA where age-appropriate
  • Injection-site assessment

What people get wrong

  • Often saidOil-based testosterone must be injected intramuscularly

    ActuallySubcutaneous injection of oil-based testosterone is well documented as effective; the IM-only belief predates the comparative evidence.

  • Often saidSubQ is just a marketing gimmick

    ActuallyAn FDA-approved subcutaneous autoinjector and multiple comparative studies support subQ as a legitimate, evidence-backed route.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

IM delivers faster absorption and larger peaks; subQ delivers a smoother curve with comparable total testosterone and, in some studies, a more favorable hematocrit/estradiol profile. Patient preference frequently favors subQ for comfort and ease of self-injection.

At a glance

SubQ needle
Often 25-30 gauge, 1/2 inch
IM needle
Longer, deeper (deltoid/glute/quad)
FDA subQ product
Xyosted (testosterone enanthate autoinjector)
Comparator trial size
234 hypogonadal men (IM cypionate vs subQ enanthate autoinjector)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Subcutaneous vs Intramuscular Testosterone. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Comparison of IM testosterone cypionate vs subQ testosterone enanthate autoinjector in hypogonadal men2021

    Both raised total testosterone significantly; subQ associated with lower post-therapy hematocrit and estradiol after adjustment

  • Subcutaneous testosterone in transgender men (JCEM)2017

    Demonstrated subQ as an effective and preferred alternative to IM